The high AUC of 0.896 indicates that transferrin has a high potential to assess the risk of functional iron deficiency in patients diagnosed with ovarian cancer, allowing for the detection functional iron deficiency even in asymptomatic patients at the initial stages of the disease, which is a signal of the onset of malignant growth and is likely to lead to the development of CRA. Here, TF is linked to Iron deficiency anemia.